Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP 78 Cash Ratio is 1.34 as of Dec. 2025, which is 53% below its 10-year median of 2.85. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.62 (Fairly Valued). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Biohit Oyj ranks better than 58.15% on this metric.
Biohit Oyj has a Cash Ratio of 1.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Biohit Oyj's Cash Ratio or its related term are showing as below:
LTS:0DRP'
s Cash Ratio Range Over the Past 10 Years
Min: 1.34 Med: 2.85 Max: 6.82
Current: 1.34
During the past 13 years, Biohit Oyj's highest Cash Ratio was 6.82. The lowest was 1.34. And the median was 2.85.
LTS:0DRP's Cash Ratio is ranked better than 58.15% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs LTS:0DRP: 1.34
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Biohit Oyj Cash Ratio Related Terms
Biohit Oyj Cash Ratio Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Cash Ratio of 1.34 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Biohit Oyj and its competitors. This is 53% below median its historical median of 2.85. Over the past decade, Biohit Oyj's Cash Ratio has ranged from 1.34 to 6.82. According to the industry distribution chart, Biohit Oyj ranks #352 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 41.9%.
Is Biohit Oyj's Cash Ratio too high?
Biohit Oyj's current Cash Ratio of 1.34 is 53% below median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 6.82. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Biohit Oyj's value of 1.34 is 38.1% above this industry median. Based on the distribution chart, Biohit Oyj ranks #352 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #352 out of 841 companies for Cash Ratio. This puts Biohit Oyj in the upper half of its industry. The industry median Cash Ratio is 0.97. Biohit Oyj's value of 1.34 is 38.1% above this benchmark. Historically, Biohit Oyj's own Cash Ratio has ranged from 1.34 to 6.82 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 0.97, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current Cash Ratio of 1.34 is 38.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Cash Ratio is 1.34, which is 53% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.62, compared to a current price of €2.65 — trading 1.1% above its estimated fair value. The current Cash Ratio is 1.34, which is 53% below median its 10-year median of 2.85 and 38.1% above the Medical Devices & Instruments industry median of 0.97. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Cash Ratio is 1.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.65 is trading 1.1% above its estimated GF Value™ of €2.62.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Cash Ratio: 1.34 (53% below median its 10-year median of 2.85)
GF Value™: €2.62 vs. price of €2.65 (1.1% above fair value)
Industry Position: 38.1% above the Medical Devices & Instruments median (#352 of 841)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
